Immuneering Corporation (IMRX)
NASDAQ · Healthcare
Immuneering Corporation Revenue 2020–2023
Immuneering Corporation annual/quarterly revenue history and growth rate from 2020 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Immuneering Corporation revenue for the quarter ending September 30, 2023 was 0, a 100.00% decrease year-over-year.
- Immuneering Corporation revenue for the twelve months ending September 30, 2023 was 38380, a 97.30% decrease year-over-year.
- Immuneering Corporation annual revenue for 2023 was 0, a 100.00% decrease from 2022.
- Immuneering Corporation annual revenue for 2022 was 316952, a 84.76% decrease from 2021.
- Immuneering Corporation annual revenue for 2021 was 2.1 M, a 10.02% decrease from 2020.
- Immuneering Corporation annual revenue for 2020 was 2.3 M.
Revenue
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Immuneering Corporation (IMRX) — Frequently Asked Questions
Immuneering Corporation (IMRX) is a publicly traded US company. It has a market capitalization of $111M. Explore IMRX's stock price, financial statements, earnings history, margins and key ratios below.
What is Immuneering Corporation's market cap?
Immuneering Corporation (IMRX) has a market capitalization of $111M.
What is the IMRX stock price?
IMRX trades at $3.92 (-2.73% on the day).
Is IMRX profitable?
In fiscal 2023, Immuneering Corporation reported net income of -$53M.